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Vascular transcriptome profiling 
identifies Sphingosine kinase 1 
as a modulator of angiotensin II-
induced vascular dysfunction
Mateusz Siedlinski1, Ryszard Nosalski1,2, Piotr Szczepaniak1, Agnieszka H. Ludwig-Gałęzowska3, 
Tomasz Mikołajczyk1,2, Magdalena Filip1, Grzegorz Osmenda1, Grzegorz Wilk1, 
Michał Nowak1, Paweł Wołkow3 & Tomasz J. Guzik1,2
Vascular dysfunction is an important phenomenon in hypertension. We hypothesized that angiotensin 
II (AngII) affects transcriptome in the vasculature in a region-specific manner, which may help to identify 
genes related to vascular dysfunction in AngII-induced hypertension. Mesenteric artery and aortic 
transcriptome was profiled using Illumina WG-6v2.0 chip in control and AngII infused (490 ng/kg/min) 
hypertensive mice. Gene set enrichment and leading edge analyses identified Sphingosine kinase 1 
(Sphk1) in the highest number of pathways affected by AngII. Sphk1 mRNA, protein and activity were 
up-regulated in the hypertensive vasculature. Chronic sphingosine-1-phosphate (S1P) infusion resulted 
in a development of significantly increased vasoconstriction and endothelial dysfunction. AngII-induced 
hypertension was blunted in Sphk1−/− mice (systolic BP 167 ± 4.2 vs. 180 ± 3.3 mmHg, p < 0.05), which 
was associated with decreased aortic and mesenteric vasoconstriction in hypertensive Sphk1−/− mice. 
Pharmacological inhibition of S1P synthesis reduced vasoconstriction of mesenteric arteries. While 
Sphk1 is important in mediating vasoconstriction in hypertension, Sphk1−/− mice were characterized 
by enhanced endothelial dysfunction, suggesting a local protective role of Sphk1 in the endothelium. 
S1P serum level in humans was correlated with endothelial function (arterial tonometry). Thus, vascular 
transcriptome analysis shows that S1P pathway is critical in the regulation of vascular function in AngII-
induced hypertension, although Sphk1 may have opposing roles in the regulation of vasoconstriction 
and endothelium-dependent vasorelaxation.
Hypertension is a pathogenetically complex disorder affecting more than 1 billion people worldwide1. Etiology 
of the disease remains unknown in the majority of adult patients. It is widely acknowledged that function of the 
vascular system, kidney and sympathetic nervous system is critical for regulating blood pressure (BP) levels1. 
Since the existence of genetic predisposition to develop abnormally high BP is well known, significant efforts have 
been made in order to identify particular genes affecting hypertension using genome-wide association studies 
(GWAS)2–5. However, clinical translation of such studies is in the early phase and requires detailed characteriza-
tion of the effect of certain genes and molecular pathways on the function of key organs involved in BP regulation.
High throughput techniques significantly contributed to unraveling mechanisms of complex disorders and 
phenotypes such as type II diabetes6, chronic obstructive pulmonary disease7 or hypertension and BP regula-
tion2–5 in humans. All the above studies focused on the association between genetic polymorphisms and dis-
ease status using Mendelian randomization concept allowing establishing causal relationships. Complexity of the 
pathogenesis of hypertension makes uncovering key drivers of the disease difficult in humans. Models of the dis-
ease such as angiotensin II (Ang II) infusion or DOCA salt hypertension, represent most common causes of pri-
mary hypertension in humans and allowed to unravel the important mechanisms of hypertension and associated 
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target organ damage. Systemic vascular resistance is critical for the physiological regulation of blood pressure. 
At the same time, hypertension promotes development of vascular dysfunction and atherosclerosis in the larger 
vessels. Importantly, while vascular oxidative stress and inflammation have been clearly linked to hypertension 
and its consequences8,9, the effects of chronic Ang II infusion on distinct vascular beds is yet to be addressed in a 
systematic manner.
Vascular dysfunction may have divergent mechanisms and consequences in various vascular beds. In the 
aorta, it may represent vascular target organ damage but may also contribute to vascular stiffening important for 
hypertension development. In mesenteric arteries, which represent typical resistance vessels, increased vascular 
tone may directly translate into increased blood pressure.
Investigation of transcriptome creates an opportunity for gaining a unique insight into potential vascular 
mechanisms of Ang II-dependent hypertension. Transcriptome profiling studies ex vivo have so far focused on 
kidneys following 2 days Ang II infusion10, heart in the model of Ang II–induced cardiac fibrosis11,12 or abdominal 
aortic aneurysm in ApoE knockout mice13. Despite the difficulties with obtaining cell-type specific and homog-
enous RNA pool, all the above studies clearly showed that Ang II displays systemic effects on transcriptome and 
important information on the disease process studied could be obtained using this high-throughput technique.
The aim of current study was to profile the transcriptome of key vessels of normotensive and hypertensive 
mice using Ang II-induced hypertension model and further to identify genes and biological pathways that may 
causally affect development of hypertension in vivo. Both thoracic and abdominal regions of the aorta, selected 
in the current study, are characterized by hypertrophy following Ang II treatment in vivo14, yet they show dif-
ferent expression pattern of Ang II receptor subtypes AT1a and AT1b15,16. This may confer differential roles of 
these areas of the aorta in hypertension15,16, thus investigation and characterization of these two regions is a key 
to the understanding mechanism of Ang II action in an in vivo model. Superior mesenteric vascular bed, which 
is another part of the vasculature selected for transcriptome profiling, is a part of the vascular resistance system, 
critical for blood flow regulation17,18. Since mesenteric arteries express AT1 receptors and are susceptible to Ang 
II-mediated dysfunction in vivo19,20, investigation of similarities and differences in gene expression in these three 
areas of vasculature may provide important molecular information on specific changes occurring during Ang 
II-mediated hypertension in vivo.
Results
Transcriptome analysis. Approximately 16,000 (out of 45,281) RNA transcripts were detected (detection 
p value < 0.01) in studied vascular tissues i.e. thoracic aorta, abdominal aorta and mesenteric arteries. Principal 
component analysis comprising RNA transcripts detected in all tissues provided a clear separation of samples 
according to tissue type and treatment status i.e. hypertensive vs. normotensive (Fig. 1a). Out of all transcripts 
expressed, 21.5% were differentially expressed (FDR corrected p < 0.05) in thoracic aorta between hypertensive 
and normotensive mice, while such proportion was lower for abdominal aorta (0.3%) or mesenteric arteries 
Figure 1. Principal component plot comprising all expressed RNA transcripts (a), differentially expressed 
RNA transcripts in all 3 tissue types (b) and heatmap of top 50 RNA transcripts affected by Ang II in vivo 
(c). (a) Top 3 principal components were calculated using expression intensities, normalized using robust 
spline normalization method, of approximately 16 000 RNA transcripts detected (detection p-value < 0.01) 
in all samples; (b) Three genes that expression is significantly changed in all 3 tissue types by Ang II infusion 
are depicted on Venn diagram, showing number of genes significantly affected by Ang II infusion in vivo in 
all 3 tissue types studied; (c) Heatmap depicts RNA transcripts most significantly affected by Ang II in vivo 
irrespectively of tissue type. Srpx = sushi-repeat containing protein, X-linked; Sphk1/2 = Sphingosine kinase 
1/2; Mfap4 = microfibrillar-associated protein 4; PC = principal component.
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(1.4%). Among differentially expressed genes 46%, 91% and 67% were overexpressed in hypertensive as compared 
to normotensive mice in the thoracic aorta, abdominal aorta and mesenteric arteries respectively.
Among top 200 RNA transcripts associated with Ang II-induced hypertension in either of the examined 
tissues, 3 genes were previously associated with BP in GWA cohort studies. Expression of both subunits of the 
soluble guanylate cyclase (Gucy1a3 and Gucy1b3) was significantly downregulated in both aortic compartments, 
but not in mesenteric arteries, in hypertensive mice as compared to control, while Cyclin M2 (Cnnm2) expression 
was significantly upregulated in mesenteric arteries of hypertensive mice as compared to control. None of the 
above genes showed a similar pattern of expression change following Ang II infusion in all vascular compart-
ments studied.
Gene set enrichment analysis identified 68 gene sets significantly enriched in hypertension in thoracic aorta 
(see Supplementary Table 1 for top 20 sets). Subsequent leading edge analysis performed on these sets identified 
genes present in the highest number of pathways upregulated in Ang II-induced hypertension (Table 1). Among 
them, only Sphk1 showed more than a 2-fold induction of expression in thoracic aorta of hypertensive mice as 
compared to control (Table 1).
Similar gene set enrichment analysis identified no pathways significantly enriched in hypertension 
in mesenteric arteries at FDR p value < 0.05. Therefore, leading edge analysis was based on 36 gene sets 
(see Supplementary Table 1 for top 20 sets) with normalized enrichment score > 1.4 (nominal p value < 0.05) in 
mesenteric arteries. This analysis also identified Sphk1 as one of the members of the highest number of gene sets 
enriched in mesenteric arteries following Ang II infusion (Table 1). Importantly, Sphk1 gene was also among the 
3 genes that changed in response to Ang II in all three vascular beds and among genes affected by Ang II infusion 
globally i.e. irrespectively of tissue type (Fig. 1b,c).
Sphk1 expression and activity in vasculature. Subsequent real-time PCR confirmed the above 
findings and showed a significant induction of Sphk1 mRNA expression in all vascular compartments stud-
ied, while no significant effects of Ang II on Sphk2 expression in vivo were observed (Fig. 2a). These increases 
translated into a significant increase in protein levels as exemplified by Western blotting (Fig. 2b and 
Supplementary Figure 1a,b). We observed a significant, yet modest, 1.8x increase in Sphk1 mRNA expression in 
hearts of Ang II-infused mice as compared to control. This induction could not be confirmed using Western Blot 
analysis (Supplementary Figure 1b,c).
Moreover, induction of vascular Sphk1 mRNA by Ang II infusion persisted when blood pressure raise was 
reduced by 76% by administration of hydralazine (Fig. 2c), indicating that increases observed were not a simple 
result of blood pressure raise but were likely caused by direct actions of Ang II in vivo.
The above observations were accompanied by a significant, 2.8x increase in sphingosine kinase activity as 
well as moderate increment in sphingosine-1-phosphate (S1P) concentration (Fig. 2d) in aortic homogenates of 
AngII-infused mice as compared to Sham control respectively.
An independent experiment focusing on different layers of thoracic aorta showed that Ang II effects on Sphk1 
expression in vivo were more pronounced in the media layer (Induction Fold (IF) = 14.2, p < 0.05) as compared to 
adventitia layer (IF = 3.6, p = 0.077) or endothelial cell -enriched fraction representing intima (IF = 4.5, p < 0.05, 
Fig. 2e). In baseline conditions expression of Sphk1 was 3.2x and 18.1x higher in the media layer as compared to 
adventitia or intima respectively (Fig. 2e).
Effects of chronic S1P infusion on vascular function in vivo. AngII-induced hypertension was accom-
panied by a significant increase in plasma S1P level in wild-type (WT) mice (Fig. 3a,b). Therefore we studied the 
effects of chronic S1P delivery in normotensive mice in vivo. Chronic S1P infusion resulted in a 35% increment 
in plasma S1P level that was accompanied by a moderate, yet not significant increase in SBP by 10 mmHg in vivo 
(p = 0.35). S1P infusion resulted in significantly elevated degree of endothelial dysfunction and vascular contrac-
tility in mesenteric arteries (Supplementary Figure 2a–c).
Thoracic aorta Mesenteric arteries
Gene
Number of gene sets 
(out of 68) log2FC
Expression change–FDR 
adj. p value Gene
Number of gene sets 
(out of 36) log2FC
Expression change–FDR 
adj. p value
Cdh13 30 0.595 0.0005 Igfbp3 9 0.17 0.11
Sphk1 29 1.221 0.0003 Eif5a 9 0.15 0.24
Sod1 29 0.191 0.0391 Inhba 8 0.19 0.39
Thy1 28 0.794 0.0013 Mast2 8 0.17 0.07
Tgfb1 22 0.284 0.0248 Cdc23 7 0.06 0.49
Nme2 21 0.283 0.0092 Ccdc88a 7 0.10 0.28
Col4a3 21 0.245 0.0278 Sphk1 7 0.40 0.04
Vegfa 20 0.330 0.0594 Apbb1 7 0.17 0.23
Angptl4 19 0.402 0.0426 Anapc5 7 0.18 0.17
Htatip2 18 0.835 0.0002 Ppp5c 6 0.09 0.41
Table 1.  Ten genes present in the highest number of gene sets most significantly enriched in hypertension 
in thoracic aorta and mesenteric arteries and their expression fold change in hypertensive mice as 
compared to normotensive mice. log2FC = logarithm of Fold Change (hypertensive vs. normotensive mice).
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Sphk1 deficiency and hypertension development in vivo. There was no significant difference 
in baseline blood pressure between Sphk1−/− and WT mice (Fig. 3a). However, upon infusion of Ang II, 
Sphk1−/− mice developed significantly less severe Ang II-induced hypertension in vivo as compared to WT 
mice (Fig. 3a). Importantly, no significant difference in heart rate was observed at both baseline conditions 
and upon Ang II infusion between WT and Sphk1−/− mice (data not shown). Following 14-days AngII infu-
sion period Sphk1−/− mice developed less severe cardiac hypertrophy as compared to WT mice (Heart to body 
weight ratio for Ang II vs. Sham groups: 5.9 ± 0.22 mg/g vs. 5.5 ± 0.15 mg/g (p = 0.15) in Sphk1−/− mice and 
6.8 ± 0.21 mg/g vs. 5.8 ± 0.21 mg/g (p < 0.05) in WT mice). This was confirmed by an analysis of cardiomyocyte 
size (Supplementary Figure 3a,b). Further analyses revealed that effects of Ang II on fibrotic changes in the heart 
as well as IMT of cardiac arteries were similar in WT and Sphk1−/− mice (Supplementary Figure 3c,d).
Effects of AngII and Sphk1 deficiency on S1P level and expression of S1P receptors S1pr1 and 
S1pr2. Sphk1−/− mice were characterized by 2–3x lower S1P plasma level as compared to WT mice (Fig. 3b) 
and approximately 30% ± 3% (p < 0.05) lower Sphk activity in the aorta. No significant compensatory effect of 
Sphk1 deletion on Sphk2 expression in vasculature was observed (data not shown). No significant effects of Ang 
II infusion or Sphk1 deletion on S1pr1 expression were observed (Fig. 3c). However, expression of this receptor 
was significantly higher in mesenteric arteries as compared to the thoracic aorta in both WT and Sphk1−/− mice 
(Fig. 3c). We observed a significant induction of S1pr2 expression in hypertensive WT mice as compared to 
normotensive WT mice in thoracic aorta (Fig. 3d). A similar trend (p = 0.07) regarding effect of AngII infusion 
was present in Sphk1−/− mice as well (Fig. 3d). Similarly, to S1pr1, expression of S1pr2 was significantly higher in 
mesenteric arteries as compared to the thoracic aorta in WT mice (Fig. 3d). Expression of S1pr3 in the aorta could 
not be detected in vessels studied.
Effects of Sphk1 deficiency and pharmacological modulation on vascular contractility. 
Pre-incubation of WT thoracic aorta with S1P significantly increased vasoconstriction of aortic rings in response 
Figure 2. Sphk activity and expression of Sphk isoenzymes in the vasculature. (a) Expression of Sphk1 
and Sphk2 mRNA analyzed by real-time RT-PCR normalized to the housekeeping Tbp gene in vascular 
compartments studied. Sphk1/Sphk2 mRNA quantity is depicted relative to the expression observed in the 
thoracic aorta of Sham group (N = 6/group); (b) Sphk1 protein expression, studied by Western blotting in 2 
independent experiments, in mesenteric arteries and aortic homogenates, that was normalized to α -tubulin 
n = 3–4/group. Detected bands and densitometric analyses are shown. Full-length blots are presented in 
Supplementary Figure 1; (c) Hydralazine (5 mg/kg/day) co-treatment effects on Sphk1 and Sphk2 mRNA 
expression in the thoracic aorta. Insert indicates changes of blood pressure upon Ang II and concomitant Ang 
II – Hydralazine treatment. n = 6/group; (d) Sphk activity (left) and S1P level (right) in thoracic aorta was 
quantified using ATP-depletion assay or competitive ELISA test respectively and results were normalized to a 
total protein content using Bradford reagent, n = 4–6/group; (e) Three layers of thoracic aorta were analysed 
in the context of Sphk1 expression as depicted in the Methods section (n = 4/group). Results were normalized 
to the relative Sphk1 expression in the adventitia of Sham group. *p < 0.05; †p < 0.05 for Sphk1 expression 
induction in AngII group vs. Sham; ‡p = 0.056 vs, Sham group; Tbp = TATA box binding protein;  
Sphk1/Sphk2 = Sphingosine kinase 1/2; Hyd = hydralazine.
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to phenylephrine (Phe) (Fig. 4a). This effect was also observed in mesenteric arteries and was also evident in 
vessels isolated from Sphk1−/− mice (data not shown). On the contrary, Sphk1 knockout led to a blunted increases 
in aortic and mesenteric arteries contractility to Phe and noradrenaline (respectively) in Ang II – hypertensive 
mice (Fig. 4b,c). In order to address this further, we studied the effects of S1P pathway modulators on vascular 
function ex vivo. Pre-incubation of mesenteric arteries with either Sphk1 inhibitor PF-543 or S1PR2 antagonist 
(JTE-013), significantly reduced Ang II-induced contraction ex vivo (Fig. 4d). Further tests performed on aortic 
rings showed that these inhibitory effects of JTE-013 on vessel contraction were dose-dependent and significant 
at a concentration of 100 nM (Supplementary Figure 4a).
Effects of Sphk1 deficiency on endothelial function and vascular superoxide anion production. 
Lack of Sphk1 was associated with a significant reduction of vasorelaxation in response to acetylcholine (Ach) in 
aortas of Ang II-infused mice (Fig. 5a) when compared to WT aortas from Ang II-infused mice. A similar trend 
was observed in mesenteric arteries (Fig. 5b). No differences in sodium nitroprusside (SNP)-induced vasodilation 
between WT and Sphk1−/− mice were observed (Supplementary Figure 4b,c). While Sphk1−/− was linked to con-
comitant enhancement of endothelial dysfunction with opposing decreased vascular contractility and moderately 
reduced blood pressure, it had no significant effect on intima media – thickness hypertrophy in Ang II-induced 
hypertension (Fig. 5c,d).
Significantly elevated CYBB (encoding Nox2 NADPH oxidase) expression in hypertensive Sphk1−/− 
mice as compared to hypertensive WT mice, both in the aorta and mesenteric arteries, was observed 
(Supplementary Figure 5a). No significant changes in Nox1 or Nox4 expression between Sphk1−/− and WT mice 
were observed (data not shown). AngII infusion significantly elevated production of superoxide anion in both 
Sphk1−/− and WT mice. However, this increment was significantly higher in Sphk1−/− mice as compared to WT 
mice (Supplementary Figure 5b). Similar experiments performed on aortic homogenates using fluorescent dihy-
droethidium (DHE) marker, showed a similar trend of association which was not significant (p = 0.22, for com-
parison of hypertensive Sphk1−/− vs WT mice).
In summary, results obtained using Sphk1−/− model and acute pharmacological modulation indicate that S1P 
generated via Sphk1 pathway exerts pro-contractile effects within vascular smooth muscle cells (VSMC) and an 
opposing protective role on the level of endothelium function.
Serum S1P levels and vascular function in humans. Serum S1P level significantly correlated with 
impaired endothelial function (lower ln (Reactive Hyperemia index-RHI)) and higher aortic systolic pressure 
(ASP) levels, in patients with cardiovascular risk, assessed by EndoPAT and SphygmoCor respectively. At the 
Figure 3. Systolic blood pressure level, plasma S1P level and expression of S1P receptors after 2 weeks of Ang 
II infusion in Sphk1−/− and WT mice in vivo. (a) Average SBP after 2 weeks of infusion of AngII (490 ng/kg/min) 
is depicted. Mice underwent non-invasive blood pressure measurement by tail-cuff plethysmography (Visitech 
BP 2000 BP Analysis System), following a period of training before commencement of the treatment protocol, 
N = 5–6 for sham groups and n = 10 for AngII groups; (b) S1P level was quantified in plasma using competitive 
ELISA kit according to the manufacturer’s instructions (Echelon Biosciences, USA), n = 6/group; (c,d) Expression 
of S1pr1 and S1pr2 was quantified in thoracic aorta and mesenteric arteries of normotensive and hypertensive 
WT and Sphk1−/− mice and was normalized to the expression of Tbp. S1pr1 and S1pr2 mRNA quantity is depicted 
relative to the expression observed in the mesenteric arteries of Sham WT group (n = 6–8/group). Expression of 
the S1pr3 receptor was not detected (Ct > 39 for all samples). *p < 0.05. Tbp = TATA box binding protein; S1pr1/
S1pr2 = Sphingosine-1-Phosphate receptor 1/2; SBP = systolic blood pressure; S1P = sphingosine-1-phosphate.
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same time, serum S1P was not significantly associated with age, sex or smoking status. No significant correlation 
between S1P and absolute office SBP, DBP, IMT, pulse wave velocity (PWV) or augmentation index (AIx) was 
observed (Table 2). Analysis of dichotomized variables showed that subjects with abnormal lnRHI (n = 20) or 
AIx (n = 19) level had significantly higher S1P level (respectively median of 22.3 (IQR:18.6–25.2) μ M and 22.3 
(IQR:16.8–25.5) μ M) as compared to the rest of subjects (respectively median of 19.4 (IQR:16.2–22.6) μ M and 
19.5 (IQR:16.2–22.8) μ M). No such association existed for dichotomized PWV level, confirming links of S1P to 
endothelial function rather than vascular stiffness.
Discussion
Bioinformatical analysis of data obtained via transcriptome profiling, employed in the current study, identified 
Sphk1 as one of the key modulators of Ang II-dependent vascular dysfunction in vivo. While numerous genes are 
altered during the development of Ang II-dependent hypertension, only Sphk1, Srpx and Mfap4 were common 
for different vascular areas studied. Sphk1 was identified as a member of numerous key biological pathways sig-
nificantly altered in hypertension and its expression was induced in major arteries following Ang II stimulation 
in vivo. Therefore we postulated that Sphk1 would play a critical role in the regulation of vascular function, BP 
increase, and consequently cardiac hypertrophy in hypertension. Indeed, using Sphk1−/− mice we observed that 
Sphk1 is causally linked with BP elevation upon chronic Ang II infusion. Ex vivo and in vivo experiments showed 
that diminished vascular contractility is a possible mechanism contributing to a partial protection from Ang 
II-induced hypertension in mice lacking Sphk1. Surprisingly, the reduction of BP increase was only moderate and 
was not associated with a significant reduction of vascular dysfunction characterized by intima-media hyper-
trophy. Further studies have identified that in opposition to overall protection from hypertension and decreased 
vascular contractility, endothelial dysfunction was significantly aggravated in Sphk1−/− mice. These results clearly 
point to the critical but very complex role of Sphk1 in the pathogenesis of Ang II-dependent hypertension and 
vascular dysfunction.
S1P is a lipid signaling molecule with numerous functions in vascular homeostasis, including signal transduc-
tion, mediating proliferation and migration of endothelial cells (EC), VSMCs and cardiac myocytes21 with a possi-
bly clinically relevant role in human diseases such as pulmonary hypertension or abdominal aortic aneurysm22,23. 
It acts via 5 known receptors and S1PR1, S1PR2 and S1PR3 are predominant in the cardiovascular system21. 
Figure 4. Contractile responses of the aorta and mesenteric arteries of WT and Sphk1−/− mice and effects of 
pharmacological inhibition of S1P pathway on vessel contraction. (a) Tissue organ bath was performed using 
2 mm aortic rings from WT mice preincubated for 5 min. with 5 μ M S1P or with control buffer (n = 4/group); 
(b,c) Tissue organ bath was performed using 2 mm aortic rings (b) or 2nd order mesenteric arteries (c) from WT 
and Sphk1−/− mice with assessment of contractile force in response to Phe normalized to an initial KCl-induced 
contraction, n = 6/group; (d) Pharmacological studies on the effects of pre-incubation with 5 μ M JTE-013 or 
100 nM PF-543 on the contraction of WT Sham mesenteric arteries were performed using tissue organ bath, 
n = 4/group; *p < 0.05 ; †p < 0.05 as compared to control group. Phe = phenylephrine; Ang II = angiotensin II; 
[M] = molar concentration.
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Sphk1 plays a critical role in the generation of S1P and Sphk1−/− mice are characterized by a systemic reduc-
tion in Sphk1 activity and depletion of S1P24,25. Identification of Sphk1 as a key member of numerous pathways 
altered in hypertension, caused by chronic Ang II infusion, is important, as it is in line with the previous report 
by Wilson and colleagues who found Sphk1−/− mice to be protected against 2-weeks model of Ang II-induced 
hypertension26, which was not confirmed in the acute model of Ang II injection27. In the current study, we found 
a somewhat smaller reduction in BP raise in Sphk1−/− mice following chronic Ang II infusion as compared to the 
previous study26, which could be caused by a slightly lower dose of Ang II-infused.
We believe that a moderate reduction in BP raise in Sphk1−/− mice observed by us is caused by opposing 
effects of S1P in the VSMCs and ECs. Previous studies have identified possible mechanisms of pro-hypertensive 
effects of Sphk1 including intracellular role of S1P in calcium entry via targeting store operated calcium chan-
nels26. Our data may support and extend these findings, since we observed both, in vivo and ex vivo, a lower 
Figure 5. Effects of Sphk1 deletion on endothelial function and intima-media thickness. (a,b) Tissue organ 
bath was performed using 2 mm aortic rings (a) or 2nd order mesenteric arteries (b) from WT and Sphk1−/− 
mice with an assessment of relaxation in response to increasing concentrations of acetylcholine. Vessels were 
precontracted using concentration of vasoconstricting agent (PGF2α or noradrenaline) required to achieve 
90% of maximal contraction as determined by testing increasing doses of certain vasoconstrictor, n = 6/group; 
(c,d) Masson’s trichrome staining of representative aortas of WT and Sphk1−/− mice (c) and comparison of 
mean IMT of all groups studied (d), n = 5 for Sham groups, n = 7 for AngII groups; *p < 0.05. WT = wild type; 
Ach = acetylcholine; SNP = sodium nitroprusside, [M] = molar concentration.
Spearman’s R coefficient p-value
LnRHI − 0.221 0.046
ASP 0.214 0.049
DBP 0.204 0.066
SBP 0.107 0.337
Average IMT − 0.044 0.696
PWV − 0.038 0.733
AIx 0.017 0.882
Table 2.  Serum S1P level and its correlations with various parameters of vascular function. RHI = Reactive 
Hyperemia Index, AIx = Augmentation Index, ASP = Aortic Systolic Pressure, S1P = sphingosine-1-phosphate, 
IMT = intima-media thickness, PWV = pulse wave velocity.
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contraction of vessels with lower activity of Sphk1 in response to Phe as compared to vessels with normal Sphk1 
activity. This indeed suggests Sphk1-mediated Ca2+ handling, since receptor-mediated membrane depolarization 
includes engagement of voltage-dependent calcium channels and the previous study demonstrated that S1P can 
activate CREB transcription factor via indirect Ca2+ influx due to inhibition of voltage-gated K+ channels in 
VSMCs28. We attempted to further identify downstream molecular targets responsible for a lower contractile 
response in vessels with diminished Sphk1 activity. We found that blocking S1PR2 receptor lowers both aortic 
and mesenteric arteries contraction in response to various stimuli. Since there is an ongoing debate concerning 
the specificity of antagonizing S1PR2 by JTE-013, which may have off-site effects especially in micromolar con-
centration29,30, we addressed this issue by testing different doses of JTE-013 and found that nanomolar concen-
trations of this antagonist reduce vascular contraction as well. However this effect likely disappears below 10 nM 
concentration of JTE-013, thus there is a need to develop a specific S1PR2 antagonist, which would facilitate 
studies on a role of this receptor in vessel contraction. The potential role of S1pr2 in AngII-mediated impairment 
of vascular function is further supported by the observed induction of expression of this receptor in the aorta of 
WT Ang II-infused mice, which consequently may partially mediate Ang II effects in vivo. Interestingly, S1pr2−/− 
mice have similar BP as compared to WT controls in basal conditions31. However, contractile responses of vessels 
of S1pr2−/− mice to KCl or Phe are impaired ex vivo and in vivo stimulation of S1pr2−/− mice with Phe unravels 
lower mesenteric and renal vascular resistance and a lower mean arterial pressure as compared to WT animals31.
However, our study reveals the complexity of the effects of Sphk1 on the regulation of endothelial function 
as well. While in VSMCs S1P-dependent calcium alterations may regulate contractility via store-operated Ca2+ 
channels26 and S1pr231, in endothelium its effects may be completely different. Our findings in in vivo hyper-
tension model suggest that S1P may be an important marker of endothelial dysfunction. Experiments using 
Sphk1−/− mice suggest that lack of Sphk1 and low plasma S1P level associates with impaired endothelial function. 
On the other hand, hypertensive WT mice display elevated S1P level, thus we tested in vivo effects of chronic 
S1P delivery. We found that elevation of S1P plasma level associates with significant impairment of endothelial 
function as well as with increased vessels contractility. It is of future interest to address exact mechanisms of this 
finding, which, among others, may include abnormal activation of S1prs in vascular media responsible for ves-
sel contraction and internalization or degradation of S1pr1 in endothelium due to high S1P level32. It has been 
shown that genetic or pharmacological inhibition of S1pr1 or S1pr3 does not impair Ach-induced relaxation33,34. 
On the other hand, agonists of S1prs such as Fingolimod or S1P may display vasorelaxant properties only when 
S1pr1 and S1pr3 are active33,34. Previous studies showed that sphingosine kinase promotes phosphorylation and 
activation of endothelial nitric oxide synthase especially via S1pr1 receptor, and associated MAPK and PI3K/
Akt pathways, in order to counteract Ang II effects and to mediate various processes such as angiogenesis35–37. 
Moreover, stimulation of S1pr1 receptor with specific S1pr1 agonist SEW2871 in vivo may lower BP in Ang 
II-induced hypertension33.
As recently shown by Cantalupo and colleagues, endothelial sphingolipid metabolism remains under control 
of Nogo-B transcription factor, which inhibits expression of serine palmitoyltransferase that participates in the 
synthesis of sphingolipids in vivo33. Mice lacking Nogo-B in endothelium were protected against Ang II-induced 
hypertension and endothelial dysfunction, which was not the case for mice lacking Nogo-B in VSMC that were 
only partially protected against Ang II-induced hypertension33. The latter effect could be explained by a reduced 
myogenic tone in VSMC-Nogo-B deficient mice. These various effects of inhibition of sphingolipid synthesis on 
vascular contractility or endothelial function can possibly explain relatively moderate, yet significant, effect of 
Sphk1 deletion on blood pressure raise in Ang II-induced hypertension in the current study, which, in our opin-
ion, deserves further investigation. Creation of VSMC and EC-specific Sphk1−/− mice would be of high value to 
dissect the role of this kinase in vascular function in vivo.
Recent work of Tölle and co-workers demonstrated that S1P plays a role in activation of human eNOS since 
both S1PR1 and S1PR3 were essential for eNOS activation in human endothelial HUVEC cells38. However, results 
from clinical studies on Fingolimod show that agonism of S1P receptors transiently lowers heart rate and SBP 
while a chronic treatment may increase SBP by 1–3 mmHg39. These effects could be attributed to the agonism 
and functional antagonism of Fingolimod towards S1PR139. To translate our findings into human population we 
quantified S1P level in a cohort of 82 subjects and found that S1P correlates with a worse endothelial function, as 
measured by lnRHI parameter. Moreover, an association of S1P level with ASP and AIx suggests that S1P may be 
a marker of vascular stiffening, although, no correlation was found with a PWV as the main indicator of arterial 
stiffness. It remains to be explored whether there is a causal relationship between S1P and the above parameters 
in prospective studies. Moreover, there is a need to confirm these findings in larger, prospective cohorts as well as 
in cohorts derived from a general population.
Our study also showed for the first time lower cardiac hypertrophy and changes in aortic superoxide anion 
production following Ang II infusion in Sphk1−/− mice. Therefore it opens another possible mechanism of 
end-organ protection in hypertension. Reduction in cardiac hypertrophy may reflect lower systolic blood pres-
sure but the extent of protection suggests additional mechanisms. Indeed S1P has been reported to be involved 
in cardiac hypertrophy and defect in models of heart failure40. Reactive oxygen species and especially superoxide 
anion are known to impair endothelial function and contribute to vascular pathology41. Several sources of super-
oxide anion in vasculature have been identified so far and include uncoupled eNOS42 or NADPH oxidases, among 
which NOX1 and NOX2 are thought to contribute to vascular pathology the most significantly41. Although stud-
ies linking S1P pathway with Nox2-mediated vascular redox imbalance in vivo are limited, it has been shown 
that sphingosine kinases regulate Nox2 activity via intracellular calcium store depletion and further S100A8/A9 
translocation in neutrophils43. Our study suggests that there is a higher expression of Nox2 NADPH oxidase in 
both aortic and mesenteric compartments of hypertensive Sphk1−/− mice as compared to WT mice. This may 
result in abnormally elevated level of superoxide anion production in Sphk1−/− mice in hypertension, yet our data 
only partially confirm this hypothesis. Since we did not find a significantly different level of superoxide anion 
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production between hypertensive Sphk1−/− and WT mice using DHE-based method, further work is required to 
determine effects of Sphk1 deficiency on redox balance in vascular tissues.
While we have focused on Sphk1 as a key driver of several pathways modified in Ang II-induced hypertension, 
our study has identified several genes and can provide a reference for future in-depth studies. The availability 
of expression of the whole transcriptome allowed many types of analytical strategies to be employed in order to 
find genes important for the development of Ang II-induced hypertension. Sphk1 was identified via gene set and 
a subsequent leading edge analyses, however, this type of analysis identified other genes that possess a known, 
important a role in BP regulation and vascular biology. T-cadherin (Cdh13), which was present in the high-
est number of significantly Ang II-affected gene sets in the thoracic aorta, is known to serve as an adiponectin 
receptor providing cardioprotective functions44. Variations in CDH13 locus were also associated with metabolic 
syndrome, adiponectin levels and BP in humans45,46. Superoxide dismutase 1 (Sod1), identified as a 3rd top gene in 
our leading edge analysis, degrades superoxide anion to peroxide. Sod1−/− mice have impaired vascular remode-
ling due to low NO bioavailability47, and SOD1 is highly expressed and functionally important in human vascu-
lature48. An attempted follow-up of the loci known to associate with BP in GWAS3, identified subunits of soluble 
guanylate cyclase and Cnnm2 among transcripts that expression was the most significantly different between 
hypertensive and normotensive mice. Soluble guanylate cyclase is a sensor of NO in VSMC, sensitive to Ang II 
stimulation, and its function in the regulation of BP is well established49,50, while Cnnm2 is relatively less studied 
in the context of hypertension and may be involved in maintaining Mg2+ balance in blood vessels51. Of impor-
tance variations in the coding region of S1PR1 locus has been recently investigated in a large cohort with respect 
to their functional role52. Interestingly, one rare variant was associated with protection from coronary artery 
disease, which implicates that variations in the function of S1P-S1PR1 pathway may be of clinical significance.
In summary, vascular transcriptome profiling employed in the present study, allowed to identify gene caus-
ally related to the development of vascular dysfunction in vivo. S1P pathway stimulation in endothelium pro-
tects against vascular dysfunction, however, inhibition of S1P pathway in VSMC decreases vasoconstriction and 
is likely responsible for the observed lower BP in Sphk1−/− mice following Ang II infusion, independently of 
endothelial function. Further studies are needed to explore the role of S1P in vascular redox balance in Ang 
II-induced hypertension. Modulation of the Sphk1 activity as well as targeting S1P receptors may provide a prom-
ising strategy for future studies aiming to prevent development of severe hypertension.
Methods
Chemicals. Ach, Phe, SNP, hydralazine hydrochloride, lucigenin, noradrenaline, and Ang II used for induc-
tion of hypertension in vivo were purchased in Sigma-Aldrich (Germany). Prostaglandin F2α (PGF2α ), JTE-013 
(S1PR2 antagonist), S1P, and Sphk1 inhibitor PF-543 were purchased in Cayman Chemical (USA).
Experiments in vivo. Male C57BL/6J (n = 24) mice were used to assess the effects of chronic Ang II infu-
sion on vascular transcriptome profile. All mice were bred in SPF animal facility. Sphingosine kinase 1 knockout 
(Sphk1−/−) (stock No: 019095) and appropriate WT control mice (stock No: 005304; C57BL/6NJ) were obtained 
from Jackson Laboratory. Twelve-week-old mice underwent either sham or Ang II (490 ng/min/kg s.c.) treatment 
for 14 days, via a surgically implanted osmotic minipump (Alzet Model 2002, Alzet Corporation, CA, USA)8,26. 
Sham treatment involved infusion of the vehicle for Ang II. During treatment, all mice underwent non-invasive 
blood pressure measurement by tail-cuff plethysmography (Visitech BP 2000 BP Analysis System), following a 
period of training before commencement of the treatment protocol8. Two weeks after pump implantation mice 
were sacrificed and tissues, i.e. aorta, 2nd and 3rd order branches of superior mesenteric artery and heart were 
collected. Genotype of Sphk1−/− mice was confirmed using real-time PCR and specific primer/probe set tar-
geting Sphk1. To investigate the dependence of studied Sphk1 responses to initial BP elevation, in a subset of 
animals hydralazine was co-administered ad libitum in drinking water at an approximate 5 mg/kg/day dose53. 
Mice received hydralazine for two weeks starting 1 day before osmotic minipump implantation. Effects of chronic 
S1P infusion on vascular function and BP were tested in normotensive mice receiving S1P solution in osmotic 
minipump for 12 days at a 300 nmol/kg/day dose. All experiments were performed according to relevant guide-
lines and Local Ethics Committee no. 1 in Kraków (Poland) approved the protocols employed (permissions no. 
151/2012, 100/2013, 254/2015 and 157/2016).
Transcriptome profiling. Isolated vessels were carefully cleaned of surrounding tissues and immediately 
placed in RNAlater solution (Ambion, USA). Two tissues of the same type and treatment status were pooled 
and RNA was isolated from such pools using Microarray RNEasy kit (Qiagen, USA), treated with DNAse I and 
quantified using Ribogreen reagent (Thermo Fisher Scientific, USA). Amplification and biotinylation of RNA 
were performed using Illumina Totalprep Amplification kit (Ambion, USA). The quality of RNA and cRNA was 
tested using Tapestation 2200 instrument (Agilent, USA), which resulted in the removal of samples not fulfilling 
quality criteria. Hybridization of cRNA to an Illumina WG-6 v.2.0 chip was performed according to the manu-
facturer protocol. Arrays were scanned on HiScan scanner (Illumina, USA). Recent GWAS that identified 29 loci 
associated with BP3 was used to check for an overlap between these loci and transcripts identified as significantly 
down- or upregulated in the current study. Transcriptomic data have been uploaded to the GEO server (series 
no. GSE75815).
Quantification of mRNA expression. Vascular RNA from selected tissues of WT and Sphk1−/− mice 
was isolated using Microarray RNEasy kit (Qiagen, USA). In an independent experiment thoracic aortas of 
hypertensive and normotensive WT mice were mechanically separated into 2, adventitia and intima-media, lay-
ers using surgical dissecting forceps under microscope without enzymatic treatment. Intima-media layer was 
then briefly perfused with 300 μ l of Qiazol (Qiagen, USA) from the inside and the resulting eluate represented 
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endothelial-enriched RNA fraction used for RNA isolation. The latter was characterized by, on average, 45x 
higher expression of Platelet/endothelial cell adhesion molecule 1 (Pecam1), 15x higher expression of Nitric Oxide 
Synthase 3 (Nos3) and 140x lower expression of Alpha 2 Actin (Acta2) as compared to the remaining intima frac-
tion. Reverse transcription was performed using 400 ng of RNA using High Capacity cDNA reverse transcription 
kit (Applied Biosystems, USA). Real-time PCR reactions were performed on the 7900HT instrument (Applied 
Biosystems, USA) using commercially available TaqMan assays for Sphk1, Sphk2, S1pr1, and S1pr3. Expression of 
S1pr2 was quantified using QuantiFast Probe Assay (Qiagen, USA). Normalized microarray expression data were 
used to test the stability of expression of 24 commonly used candidate genes using Normfinder ver. 0.953 software 
(Supplementary Table 2)54. In this way, TATA box binding protein (Tbp) was selected as a constitutive gene for 
all real-time PCR experiments due to a high number of probes present on a chip and high stability of expression 
across all tissues examined.
Western blotting. Immunoblotting was used to examine expression of Sphk1. Snap-frozen aortas, hearts 
and mesenteric arteries were homogenized in lysis buffer (in mmol/L: sodium pyrophosphate 50, NaF 50, NaCl 
5, EDTA 5, EGTA 5, HEPES 10, Na3VO4 2, PMSF 50, Triton 100 0.5%, and leupeptin, aprotinin and pepstatin, 
all 1 mg/mL). Proteins extracted from each lysate (30 μ g) were separated by electrophoresis on 12% SDS poly-
acrylamide gel, and transferred to a nitrocellulose membrane. For immunoblotting, nonspecific binding sites 
were blocked with 5% Bovine Serum Albumin in Tris-buffered saline solution for 1 hour at room temperature. 
Membranes were then incubated with specific antibodies (anti-Sphk1 (Cell Signalling, no. 3297), anti-α -tubulin 
(Abcam, no. ab4074), anti-GAPDH (Abcam, no. ab8245) or anti-β -actin (A5441, Sigma-Aldrich) overnight at 
4 °C (TBS-T, 5% BSA). After incubation with secondary antibodies for 1 hour at room temperature, signals were 
revealed with fluorescence using IRDye® 800CW donkey anty-rabbit secondary antibodies and quantified densi-
tometrically with Odyssey ClX Imaging system and Image Studio Lite (ver. 5.2) software.
Vascular function studies. Vascular reactivity was measured using 750 TOBS instrument (DMT, Denmark) 
in isolated 2 mm segments of the aorta in organ chambers as previously described8. Contraction of 2 mm aortic 
segments in response to increasing concentrations of Phe was tested. Endothelium-dependent relaxations to Ach 
was measured in similar segments of the aorta in organ chambers as reported8. In some experiments mesenteric 
arteries were pre-incubated for 30 min. in KREBS buffer containing 5 μ M of JTE-013 or 100 nM PF-543, while 
control rings were incubated with vehicle (0.1% DMSO). Experiments concerning mesenteric arteries and their 
contraction in response to Ang II or noradrenaline and relaxation in response to Ach were performed using 
610 M myograph (DMT, Denmark).
Vascular superoxide production. Superoxide production was measured using lucigenin- enhanced chemi-
luminescence (LgCL). The harvested aortic segments, stored on ice, were cut open to expose endothelial surface 
and equilibrated for 30 min in aerated Krebs-HEPES buffer at 37 °C. LgCL from intact vessels was measured in 
2 ml buffer containing low concentration lucigenin (5 μ M) using Berthold FB12 luminometer. Superoxide pro-
duction was expressed as relative light units (RLU) per second per mg of dry weight of the vessel. An alternative, 
DHE-based method was used to quantify superoxide anion production in aorta homogenates of AngII-infused 
WT and Sphk1−/− mice (n = 5 for both groups)55. Fluorescence measurements were performed in 37 °C using 
Synergy H4 instrument. Protein content in homogenates was normalized using Bradford reagent.
Heart and aorta histology. Aortas and hearts were fixed using formalin solution and stored in 70% EtOH. 
Fixed tissues were stained using Masson’s trichrome (Sigma-Aldrich, Germany) according to the manufacturer 
protocol. ImageJ (ver. 1.49)56 was used to quantify intima-media thickness (IMT) in cross-sectional sections of 
aorta and area of cardiomyocytes in cross-sectional sections of hearts. We also quantified IMT of cardiac arter-
ies of similar size in the left ventricle (diameter of approximately 100 μ m; 1–2 arteries per heart) and percent of 
fibrotic changes in heart sections using ImageJ.
Quantification of S1P level and Sphk activity. Mouse aortas were homogenized for 10 min. in lysis 
buffer with protease inhibitor cocktail in TissueLyser LT bead mill (Qiagen, USA). Homogenates were centri-
fuged for 10 min. (6000 g) and resulting supernatant was used to quantify sphingosine kinase activity using ATP 
depletion assay according to the manufacturer’s instructions (Echelon Biosciences, USA). Amount of total pro-
tein in supernatants was quantified with Bradford reagent (Sigma, Germany) and normalized. Mouse blood was 
collected from right ventricle using heparin as an anticoagulant. Plasma was collected after 10 min. of centrifu-
gation at 2000 g. Level of S1P in mouse plasma, mouse aortic homogenates (prepared as described above) and 
human serum was quantified using competitive ELISA test according to the manufacturer instructions (Echelon 
Biosciences, USA).
Patients characteristics. Eighty two patients (Supplementary Table 3) were recruited in the J. Dietl 
Hospital in Kraków (Poland) and E. Szczeklik Hospital in Tarnów (Poland). Inclusion criteria included age 
(40–80 years), at least one, documented and conventional, risk factor to develop atherosclerosis and patient’s 
informed consent to participate in the study. The most import exclusion criteria included: lack of patient’s con-
sent, positive history of major cardiovascular/lung diseases (such as pulmonary hypertension, ischaemic heart 
disease, stroke, cancer, chronic heart failure, atrial fibrillation, COPD, bronchial asthma), positive inflammatory 
status (based on medical documentation or CRP level ≥ 10 mg/l), steroid or immunosuppressive therapy in the 
last 5 years, pregnancy, breastfeeding, alcoholism, menopause or post-menopausal period with use of hormonal 
therapy. RHI was assessed using EndoPAT device (Itamar Medical, Caesarea, Israel). RHI was natural log trans-
formed and was analyzed as a continuous variable as well as binary variable according to the recommended cutoff 
point (i.e. lnRHI≥ or < 0.51). AIx, PWV and ASP were assessed using SphygmoCor device (Atcor Medical Pty 
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Ltd, Australia). PWV, AIx and ASP were analyzed as continuous variables as well as binary variables according to 
the cutoff points calculated by SphygmoCor software for absolute values normalized to age, sex, SBP, height and 
weight. Average IMT of the carotid artery was measured using ultrasound imaging. This study was conducted 
according to the Declaration of Helsinki and was approved by the Jagiellonian University Bioethics Committee 
(approval no. KBET/7/B/2014).
Statistical analyses. Analyses of transcriptome profiles were performed in R (ver. 3.0.2) using lumi, limma 
and gplots packages57. RNA transcripts expression intensities were normalized using a robust spline normaliza-
tion method. In order to find RNA transcripts globally affected by Ang II in vivo additional analysis comprising 
all samples with adjustment for tissue type was performed. Gene set enrichment analysis was performed using 
GSEA software (ver. 2.1.0) and Gene Ontology biological process set58,59. Subsequent leading edge analyses were 
performed on gene sets that were either significantly (FDR p < 0.05) enriched in hypertension (thoracic aorta) or 
showed normalized hypertension enrichment score > 1.4 (mesenteric arteries). All remaining statistical analyses 
were performed in IBM SPSS statistics software (ver. 23). For comparison of the effects of Ang II on parameters 
in different groups of mice, we employed two-way ANOVA or Student’s t tests. Analysis of organ chamber exper-
iments was performed using repeated measures ANOVA. Associations between S1P level and clinical parameters 
were tested using Mann-Whitney U test or Spearman’s correlation test. Data are presented as means ± standard 
error of the mean. P values < 0.05 were considered significant.
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